6th May 2021
- 0 comments
Mogrify Limited, a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has completed the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.